Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease

The blood–brain barrier (BBB) is a major obstacle to the development of effective therapeutics for central nervous system (CNS) disorders, including Alzheimer’s disease (AD). This has been particularly true in the case of monoclonal antibody (mAbs) therapeutic candidates, due to their large size. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagnon, Maxime, Savard, Martin, Tran, Thi Minh Hue, Vincent, Laurence, Moquin, Alexandre, Tremblay, Philippe, Roucou, Xavier, Dory, Yves, Gobeil, Fernand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10343654/
https://www.ncbi.nlm.nih.gov/pubmed/37446867
http://dx.doi.org/10.3390/molecules28135206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10343654/
https://www.ncbi.nlm.nih.gov/pubmed/37446867
http://dx.doi.org/10.3390/molecules28135206

Ejemplares similares